Ka U. Ip
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ka U. Ip has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chu-Xia Deng
Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China
83 shared publications - Chen Huang
Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR 999078, China
82 shared publications - Chengcheng Song
CRDA, Faculty of Health Sciences, University of Macau, Taipa, Macau
82 shared publications - Dongliang Leng
CRDA, Faculty of Health Sciences, University of Macau, Taipa, Macau
82 shared publications - Guokai Chen
Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau
82 shared publications - Heng Sun
CRDA, Faculty of Health Sciences, University of Macau, Taipa, Macau
82 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2888
Dasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling
Background/Objectives: Developing effective therapies for patients with triple-negative breast cancer (TNBC) remains an urgent clinical priority. Compared with other subtypes, the basal B type of TNBC exhibits a less differentiated and mesenchymal-like phenotype that models highly invasive and metastatic breast malignancies. To target metastatic TNBC, our current study sought to identify effective therapeutic drugs and the underlying mechanisms. Methods: A systematic screening of 140 FDA-approved drugs was conducted for repurposing using live-cell imaging-based wound-healing assays. Candidate efficacy was validated by in vitro transwell invasion assays, in vivo allograft/xenograft models, and ex vivo three-dimensional air–liquid interface (ALI) and patient-derived organoid (PDO) cultures. Results: Dasatinib emerged as a promising anti-cancer agent in aggressive TNBC, particularly in the basal B type, with high ETS proto-oncogene 1 (ETS1) expression. Mechanistically, dasatinib disrupts the actin cytoskeleton, impairing cell motility and migration while concurrently suppressing the expression of ETS1 and matrix metalloproteinase-3 (MMP3) to remodel the extracellular matrix (ECM) and inhibit invasion. Moreover, the combination of dasatinib with an anti-programmed cell death protein-1 (PD-1) antibody represents a potential therapeutic strategy. Conclusions: These findings highlight dasatinib as a potential therapeutic option for metastatic TNBC and suggest that selecting patients with high ETS1 expression may optimize treatment response.
- 26 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2888
Open AccessDasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling
Background/Objectives: Developing effective therapies for patients with triple-negative breast cancer (TNBC) remains an urgent clinical priority. Compared with other subtypes, the basal B type of TNBC exhibits a less differentiated and mesenchymal-like phenotype that models highly invasive and metastatic breast malignancies. To target metastatic TNBC, our current study sought to identify effective therapeutic drugs and the underlying mechanisms. Methods: A systematic screening of 140 FDA-approved drugs was conducted for repurposing using live-cell imaging-based wound-healing assays. Candidate efficacy was validated by in vitro transwell invasion assays, in vivo allograft/xenograft models, and ex vivo three-dimensional air–liquid interface (ALI) and patient-derived organoid (PDO) cultures. Results: Dasatinib emerged as a promising anti-cancer agent in aggressive TNBC, particularly in the basal B type, with high ETS proto-oncogene 1 (ETS1) expression. Mechanistically, dasatinib disrupts the actin cytoskeleton, impairing cell motility and migration while concurrently suppressing the expression of ETS1 and matrix metalloproteinase-3 (MMP3) to remodel the extracellular matrix (ECM) and inhibit invasion. Moreover, the combination of dasatinib with an anti-programmed cell death protein-1 (PD-1) antibody represents a potential therapeutic strategy. Conclusions: These findings highlight dasatinib as a potential therapeutic option for metastatic TNBC and suggest that selecting patients with high ETS1 expression may optimize treatment response.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S13. Univariate and multivariable Cox regression analysis of nodes involved in the prognostics related ceRNA network.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S13. Univariate and multivariable Cox regression analysis of nodes involved in the prognostics related ceRNA network.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S6. GO analysis for DE genes between C1(Low) and High(C2).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S6. GO analysis for DE genes between C1(Low) and High(C2).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Figure S2. Validation of subtypes of SARC using Consensus clustering analysis.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Figure S2. Validation of subtypes of SARC using Consensus clustering analysis.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S9. DE miRNAs in C2 (High) compared with C1 (Low).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S9. DE miRNAs in C2 (High) compared with C1 (Low).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S17 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S17. CD4+/CD8+ T cells infiltration levels in tumor tissues of mice bearing with S180.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S17 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S17. CD4+/CD8+ T cells infiltration levels in tumor tissues of mice bearing with S180.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S16. Cell types determination based on different annotation references.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S16. Cell types determination based on different annotation references.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S12. MREs between mRNAs and miRNAs in the survival-related ceRNA network.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S12. MREs between mRNAs and miRNAs in the survival-related ceRNA network.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S15. Pearson Correlation Coefficient between target lncRNA and target mRNA of key miRNAs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S15. Pearson Correlation Coefficient between target lncRNA and target mRNA of key miRNAs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S1. PCR primers of the 10 genes in the subnetwork for cell line experiments.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S1. PCR primers of the 10 genes in the subnetwork for cell line experiments.